Cyclin D as a therapeutic target in cancer - Test2 - elhamkhani - TriplyDB

Cyclin D as a therapeutic target in cancer

Cyclin D as a therapeutic target in cancer

http://www.wikidata.org/entity/Q28242623

about

Protein kinase C signaling and cell cycle regulation Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis Role of EBNA-3 Family Proteins in EBV Associated B-cell Lymphomagenesis Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer Targeting CDK6 in cancer: State of the art and new insights SAM68: Signal Transduction and RNA Metabolism in Human Cancer Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors NIRF/UHRF2 occupies a central position in the cell cycle network and allows coupling with the epigenetic landscape The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis Genetic variations in colorectal cancer risk and clinical outcome Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets Gene expression signature of DMBA-induced hamster buccal pouch carcinomas: modulation by chlorophyllin and ellagic acid Growth inhibition of head and neck squamous cell carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE gene silencing The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer Cell Death in Chondrocytes, Osteoblasts, and Osteocytes Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents A novel role for the cell cycle regulatory complex cyclin D1-CDK4 in gluconeogenesis Targeting CDK4 and CDK6: From Discovery to Therapy MicroRNA-101 is a potential prognostic indicator of laryngeal squamous cell carcinoma and modulates CDK8 Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis Sustained proliferation in cancer: Mechanisms and novel therapeutic targets CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer Regulation of cyclin D2 expression and degradation by follicle-stimulating hormone during rat granulosa cell proliferation in vitro Subnuclear cyclin D3 compartments and the coordinated regulation of proliferation and immunoglobulin variable gene repression Chd5 requires PHD-mediated histone 3 binding for tumor suppression A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network Stochastic modeling suggests that noise reduces differentiation efficiency by inducing a heterogeneous drug response in glioma differentiation therapy Switching off malignant mesothelioma: exploiting the hypoxic microenvironment Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer.Selective inhibition of tumor oncogenes by disruption of super-enhancers Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data.Expression and Therapeutic Potential of SOX9 in Chordoma.

P2860

Q21131217-42CBD690-038F-4703-8B63-98FE86D92722 Q23913301-231F7B72-90BA-45DF-B87D-4EF10C6A4142 Q26752541-96372E64-78B7-4CAA-ADBF-074A03F10BD3 Q26778509-AD7D793A-5AB8-4E05-9B67-785A382A3402 Q26796499-4D541AF4-1C6E-4234-AFB8-9540164023DA Q26798149-07B3B189-6E7E-4691-94B6-21F021FD117B Q26824298-6BFEFE05-71F5-4B75-942A-2CC659A27C5D Q26827580-EA198CF0-325E-4497-B68D-AA9ECE7104C2 Q26851503-3CFB5581-0025-49DD-8DB4-1F1D9AF7759E Q26865888-424C60D2-2F38-4BAC-B860-BD900373B595 Q27002944-6C6C6205-CF62-4201-841A-802946AB2AC7 Q27004250-218485F0-D339-46D7-94A8-D69E9030677A Q27305099-3DBF98A8-8738-4A23-9325-F9E13044D352 Q27322637-211CD135-BC93-4C81-94F8-47AB8657A25F Q27684613-9A4E6F1F-6D6A-414F-8E73-053AA25B776C Q28067045-B3A6DBA7-753B-414E-BDF4-A251B8EB4A69 Q28069910-F02804F7-BB5F-4CF6-B33A-824AE82A6138 Q28075606-A3489A22-C596-4EF6-9DC5-DF73287F3A41 Q28077336-7314E52E-0DE5-45D1-A152-F4AADFE6D4D3 Q28082912-BFA68620-873D-447C-959A-ABC52E80D9A8 Q28266383-46E41FAC-1663-46D0-A27B-6AAE833B284E Q28279753-8202A1BC-C3B9-4E15-A867-6EEDBDBD7969 Q28296641-3197C9EF-44AA-454C-B9DF-086C00BC8989 Q28396388-8B43F9BE-58BA-4DE9-BA0D-16E8058D9E43 Q28533417-CD2A7D26-07EA-424D-AD47-37B46F0194DA Q28536066-3CBF9240-17B5-41CC-95D1-25CA3B15D240 Q28543608-7D570327-64CC-4ED9-B813-36FC9262CDAC Q28571887-B72F0486-3639-4E2A-A7EC-13AFED52C7E9 Q28585407-72BC6A7D-355B-49EE-8BA9-67B533B00387 Q28593132-C0C64014-130D-4A84-B33F-1CA8E94F6AE6 Q28817426-2DFA7995-E1F0-40D9-AF5C-FB24EB3C9A75 Q28830465-766AF225-0EAC-443F-901A-D48BDC674F4A Q29248727-B7D20F34-10CE-4DD7-AA0B-38F47877B3A3 Q29417117-40D299FA-7853-44F2-9D4B-7325E593B314 Q29617301-B9BC0018-4FE0-45B9-8489-8341D6D5A57C Q30395891-D95C93B7-ED36-4648-928D-6DEE1224804E Q30426051-D94D203F-E0EB-453B-B39A-507F03C2E9DC Q30587011-97061326-A84D-4034-AFD9-46B0763C17E9 Q30964474-C60FE7AD-D30B-4908-ADF5-83D6A2DC9A12 Q33276544-4B32FEE9-B5B3-47F8-B914-2A6057019C56

P2860

Cyclin D as a therapeutic target in cancer

http://www.wikidata.org/entity/Q28242623

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cyclin D as a therapeutic target in cancer

@ast

Cyclin D as a therapeutic target in cancer

@en

Cyclin D as a therapeutic target in cancer

@nl

type

label

Cyclin D as a therapeutic target in cancer

@ast

Cyclin D as a therapeutic target in cancer

@en

Cyclin D as a therapeutic target in cancer

@nl

prefLabel

Cyclin D as a therapeutic target in cancer

@ast

Cyclin D as a therapeutic target in cancer

@en

Cyclin D as a therapeutic target in cancer

@nl

P1433

Q28242623-FCF761DD-3F94-4168-B5D7-77322ED4B96E

P1476

Q28242623-4BBF4E29-25ED-4972-8496-6574CD488596

P2093

Q28242623-21E838DF-AF48-4D2D-B2D9-6802EBAD6C56

Q28242623-26CB1185-33EF-481D-8014-65E9002A3C04

Q28242623-947DB165-1A92-4F94-A4A6-79E9AC139A00

Q28242623-DBDC5E62-BB00-4286-858A-98F17C205B26

Q28242623-DCAB63FB-CB7E-4ABC-A321-56AF8D0B1CCC

P2860

Q28242623-019CD413-43A0-4E96-B6DD-C5FA8F1E9D6B

Q28242623-01E882D7-0B38-4AF9-8AB5-CF5855033DDC

Q28242623-02726746-B6AA-4A7E-B385-3048F8489E83

Q28242623-028E16A6-19F6-4D3D-A9A0-DF7DDF2F2E44

Q28242623-03565CA3-A568-4540-9B82-D4BEB1D3CBD4

Q28242623-0436BDCE-02E2-4110-8DB1-5484C1B77EC3

Q28242623-04F84F45-9C73-4F87-B4AA-EA2D0D89F01C

Q28242623-0670082D-F1A6-4B17-8E3C-490D70342A2A

Q28242623-06EDDEB6-7582-43FC-BF64-53066B398FEA

Q28242623-083D8804-329E-4EE9-8A5B-CD95EEEA7CC7

P2888

Q28242623-F3827C9C-CF8D-48ED-AB42-31439095A8FD

P304

Q28242623-CDEFB3E4-C17D-4F55-A367-DA2DE14A53D7

P31

Q28242623-C0353CD9-794E-475D-9A54-FE2972BE98C9

P3181

Q28242623-E0058193-34EA-4ECF-AC10-C6BAE0AF5D84

P356

Q28242623-359E9961-AF97-4102-A71D-025BD182FAB2

P407

Q28242623-9F5C4C5E-5627-4A24-A9EE-7B1F2AE9066B

P433

Q28242623-306D532F-6919-47AF-916F-985FB1111CB4

P478

Q28242623-3C7321A9-D1BD-4CD4-AE9B-3482882BDA10

P577

Q28242623-A1D93F2A-2BC2-44B6-81B3-D8E19AE0799A

P6179

Q28242623-F59EAA33-E745-4ED1-A07F-02C7FD748F44

P698

Q28242623-055ED717-4CDF-40F4-ACCE-228DB714B76C

P3181

P356

P1433

Nature Reviews Cancer

P1476

Cyclin D as a therapeutic target in cancer

@en

P2093

Andrew Stone

http://www.w3.org/2001/XMLSchema#string

C Elizabeth Caldon

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Musgrove

http://www.w3.org/2001/XMLSchema#string

Jane Barraclough

http://www.w3.org/2001/XMLSchema#string

Robert L Sutherland

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention

Hallmarks of Cancer: The Next Generation

Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells

Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis

Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase

Cell cycle, CDKs and cancer: a changing paradigm

Suppression of cancer cell growth by promoting cyclin D1 degradation

Identification of G1 kinase activity for cdk6, a novel cyclin D partner

Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice

P2888

P304

558-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

417078

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRC3090

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1034487211

http://www.w3.org/2001/XMLSchema#string

P698

21734724

http://www.w3.org/2001/XMLSchema#string